Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review
Y Luo, X Cai, B Yang, F Lu, C Yi, G Wu - Frontiers in Oncology, 2024 - pmc.ncbi.nlm.nih.gov
Abstract Lymphocyte activation gene 3 (LAG-3), also known as CD223, is an emerging
immune checkpoint that follows PD-1 and CTLA-4. Several LAG-3 targeting inhibitors in …
immune checkpoint that follows PD-1 and CTLA-4. Several LAG-3 targeting inhibitors in …
Effects of immune checkpoint blockade on antigen‐specific CD8+ T cells for use in adoptive cellular therapy
Adoptive T‐cell therapies have been successfully used as prophylaxis or treatment for
immunocompromised patients at risk of viral infections or advanced cancers. Unfortunately …
immunocompromised patients at risk of viral infections or advanced cancers. Unfortunately …
An overview of multiplexed analyses of CAR T-cell therapies: insights and potential
BP DePriest, N Vieira, A Bidgoli… - Expert review of …, 2021 - Taylor & Francis
Introduction Cancer immunotherapy is a rapidly growing field with exponential advancement
in engineered immune cell-based therapies. For instance, an engineered chimeric antigen …
in engineered immune cell-based therapies. For instance, an engineered chimeric antigen …
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents
M Perez-Santos, M Anaya-Ruiz… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction LAG-3 is considered to be the third point of immunological control in relation to
clinical trials that address cancer treatment, only behind PD-1 and CTLA-4, due to its role as …
clinical trials that address cancer treatment, only behind PD-1 and CTLA-4, due to its role as …